White Papers, Case Studies, Reports
Rewriting the Future of Clinical Trials: AI, Agility, and the Portfolio-First Mandate
In a rapidly changing research landscape, leaders at Takeda, Novartis, Sanofi, Daiichi Sankyo, and Medable share firsthand insights into how artificial intelligence is reshaping clinical trial operations.
This exclusive whitepaper explores how forward-thinking organizations are reimagining trial design, execution, and scaling to meet the demands of speed, precision, and patient-centricity across their entire portfolio.
Case study: Removing translation bottlenecks with AI
Traditionally, translations and language migration create significant bottlenecks on the path to trial study go-live. The process is traditionally manual, linear, and resource intensive. To address these challenges, Medable partnered with Lionbridge, a leading translation services company to compare the status quo translation process against an AI-enabled approach powered by both companies’ proprietary new AI tools.
Case Study: Medable, CRO, & pharma partner to accelerate clinical trial deployment at scale
A top-3 contract research organization (CRO) and a top-10 pharmaceutical company partnered with Medable to help accelerate the speed, scale, and standardization of their eCOA trials.
The two organizations had been hampered by lengthy configuration timelines, inconsistent designs across studies, and siloed processes between sponsors and their CRO partners.
By centralizing the sponsor’s preferred instruments and configurations into a reusable digital library, Medable enabled the CRO to rapidly accelerate its portfolio development and initiate new studies without starting them “from scratch.”
Complete the form to get your copy of the case study and see how we enable rapid acceleration for CROs.
Accelerating oncology research: Digital strategies for modern clinical trials
Learn how digital tools ease oncology research for all stakeholders while accelerating the pace of research with this whitepaper.
Case study: Medable reduces trial build from weeks to days
A top global clinical research organization (CRO) partnered with Medable to transform its approach to clinical trial building. Recognizing the inefficiencies in traditional build processes that often “take weeks,” the client leveraged Medable’s Studio platform with its latest AI capabilities to dramatically accelerate timelines, enhance transparency, and improve quality.
Case study: Setting a new client standard in study closeout timelines
A top-10 global pharmaceutical company partnered with Medable for their pivotal Phase III diabetes study in the highly competitive market. Recognizing the inefficiencies in traditional study delivery and closeout processes, the company leveraged Medable’s expertise to accelerate timelines, enhance operational efficiency, and achieve a faster time to market for this high-profile therapy.
AI in Clinical trials - Key insights from industry experts
When OpenAI unveiled ChatGPT in November 2022, it ignited unprecedented interest in artificial intelligence. Three years later, generative AI and machine learning have caused seismic shifts in industries worldwide. The pharmaceutical industry is not left out of this shift, with Roots Analysis reporting that they expect AI within clinical trials to grow at a compound annual growth rate of 16% through 2035. This growth is driven by belief in AI’s unique ability to process and analyze massive datasets at groundbreaking speeds, identifying patterns and generating insights that would be impossible to discover through traditional methods. By leveraging these capabilities, pharmaceutical companies hope to fundamentally reimagine core aspects of clinical trials, from initial design through final data analysis.
Case study: Medable beats forecasted FPI date while raising eCOA adherence in Japan
A top-10 global pharmaceutical company aimed to address eCOA adherence and patient enrollment challenges faced by clinical trial sites and participants in Japan.
Recognizing Japan’s distinct regulatory, cultural, and logistical landscape, the company partnered with Medable todevelop an initiative to enhance the region’s patient and site experience.
Challenge fuels change: Medable impact report
Medable’s 2024 was a year of exceeding key milestones and helping our customers reach new heights.
Take a look at the difference Medable has made with our year-end impact report.
Case Study: Medable beats forecasted FPI date by taking eCOA off the critical path
A top-10 global pharmaceutical company came to Medable looking to standardize and scale their weight management trials. The trial was driven by a master protocol with multiple sub-studies across 70+ research sites.
The partner was concerned about the participant and site experience, particularly participant enrollment and study startup timelines, as the trial required participants to enroll through the master protocol before enrolling into a sub-study.
Read ahead to see how Medable accomplished this, beat the forecasted FPI date, and more.
.jpg)
Rapid evolution: Clinical trials have gone digital
DCT and digital elementsare now the new normal. But what exactly does "digital" or "decentralized" mean in the context of clinical trials?
A panel of industry experts from Sanofi, Bayer, and the Clinical Trials Transformation Initiative (CTTI) recently came together to discuss the evolution of DCTs and share their experiences.
Efficient & empathetic: New Duke research shows the real power of eConsent
With the eConsent market expected to continue its ascent over the next ten years, it’s apparent to those who have used it that the “e” in eConsent stands for much more than electronic.
Analysis and real-world examples show that it can be efficient, educational, and empathetic, leading to better participant education, reduced participant dropout, lower administrative burden for sites, reduced audit findings, and more.
Complete the form below to grab your copy of our whitepaper and see what Duke had to say.
Explore Medable Studio
A decade ago, our founders’ experiences in clinical research and life sciences drove them to create Medable, a simple cloud-based platform that could improve theconduct of trials. Over the last ten years, we’ve conducted nearly 400 trials on our platform, continually refining it to provide a better experience for sites, patients, and caregivers.Today, we’re excited to announce that our customers are entering a new era of control, ease of use, and simplicity.